Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Non-Small-Cell Lung 55Carcinoma, Hepatocellular 54Lung Neoplasms 32Small Cell Lung Carcinoma 28Neoplasms 25Breast Neoplasms 20Colorectal Neoplasms 18Melanoma 15Urinary Bladder Neoplasms 13Triple Negative Breast Neoplasms 13Carcinoma, Transitional Cell 13Neoplasm Metastasis 12Carcinoma, Renal Cell 12Squamous Cell Carcinoma of Head and Neck 10Prostatic Neoplasms 9Uterine Cervical Neoplasms 8Glioblastoma 8Stomach Neoplasms 7Endometrial Neoplasms 7Ovarian Neoplasms 6Head and Neck Neoplasms 6Sarcoma 5Pancreatic Neoplasms 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5Liver Neoplasms 4Kidney Neoplasms 4Extensive Stage Lung Small Cell Carcinoma 4Carcinoma 4Brain Neoplasms 4

Interventions

pembrolizumab 6Cetuximab 5olaparib 3atezolizumab 3Injections 3fludarabine 2Trastuzumab 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2zimberelimab 1zansecimab 1tocilizumab 1taxane 1spartalizumab 1somatostatin receptor 2 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1lenvatinib 1ipatasertib 1inavolisib 1fludarabine phosphate 1entrectinib 1encorafenib 1durvalumab 1dapagliflozin 1cemiplimab 1brigimadlin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumors × atezolizumab × 1 year × Clear all
NCT04303858 2026-06-02

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
189 enrolled
Other solid neoplasm

Solid Tumors

NCT04250155 2026-05-26

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Active not recruiting
195 enrolled
Other solid neoplasm

Solid Tumors

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡